Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Glucose monitoring after Acute Myocardial infarct in people with diabetes is a Dexcom funded study that is investigating whether the use of continuous glucose monitors (Dexcom ONE model) in people with type 2 diabetes facilitates time in glycaemic range in the 6 months after an acute myocardial infarction. As an exploratory outcome it will investigate whether time in glycaemic range is associated with changes in mortality and major adverse cardiac events in the 6 months after acute myocardial infarct.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ From the Hammersmith Hospital In-patient Cardiology Services:

• Adults aged \>18 years

• Known or newly diagnosed type 2 diabetes

• Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and/or insulin

• Admitted to Hammersmith Hospital cardiology inpatient services with ACS

• Raised blood troponin level on admission

⁃ From Imperial College Healthcare Trust Diabetes and Cardiology Clinics:

• Adults aged \>18 years

• Known type 2 diabetes

• Previous acute coronary syndrome within the last 10 years but \> 6 months ago

• Taking one or more oral hypoglycaemic agent and /or GLP1 receptor analogue, and/or insulin

Locations
Other Locations
United Kingdom
Hammersmith Hospital inpatient cardiology services
RECRUITING
London
Contact Information
Primary
Monika Reddy, MBChB, PhD
m.reddy@imperial.ac.uk
020 3311 1062
Backup
Nick Oliver, MB BS, BSc
nick.oliver@imperial.ac.uk
Time Frame
Start Date: 2023-02-07
Estimated Completion Date: 2025-02
Participants
Target number of participants: 160
Treatments
Experimental: Real time CGM post acute myocardial infarct
Real time Dexcom ONE CGM system to be applied for 26 weeks post acute myocardial infarct. Option for participants in this group to continue using rCGM in an open label observational extension phase for a total of 3 years.
No_intervention: Blinded CGM post acute myocardial infarct
Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment, and then at days 17-23, week 10 and week 24. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. CGM measurements will be blinded until the end of the study. Management of diabetes in this cohort as per usual standards of care.
No_intervention: Blinded CGM historical acute myocardial infarct (>6 months and <10 years ago)
Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. Management of diabetes in this cohort as per usual standards of care.
No_intervention: Cardiovascular outcomes control group
Age and sex-matched controls from the NIHR Cardiovascular Health Informatics Collaborative.
Authors
Neil Hill
Related Therapeutic Areas
Necrosis
Type 2 Diabetes (T2D)
Heart Attack
Sponsors
Leads: Imperial College London

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Study of Microvascular Dysfunction, Coronary Flow Reserve and Cardioprotective Effect of Early Intravenously Administration of Esmolol in Patients With Myocardial Infarction

Study of Microvascular Dysfunction, Coronary Flow Reserve and Cardioprotective Effect of Early Intravenously Administration of Esmolol in Patients With Myocardial Infarction

Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Drug
Study Phase: Not Applicable

Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Segment Elevation Myocardial Infarction (STEMI) (DISTEMI Study)

Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Segment Elevation Myocardial Infarction (STEMI) (DISTEMI Study)

Enrollment Status: Recruiting
Publish Date: August 22, 2023

Selective C-reactive Protein Apheresis in ST-elevation Myocardial Infarction

Selective C-reactive Protein Apheresis in ST-elevation Myocardial Infarction

Enrollment Status: Recruiting
Publish Date: May 09, 2025
Intervention Type: Device
Study Phase: Not Applicable
View All